Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy 27th Annual Meeting

Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that six abstracts highlighting preclinical data from its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms have been accepted for presentation, including one oral presentation, at the American Society of Gene and Cell Therapy (ASGCT) 27 th Annual Meeting taking place May 7-11, 2024 in Baltimore, MD.

"We are delighted to have a robust presence at this year's ASGCT meeting and showcase some of the innovative technical work underpinning the breakthroughs we have achieved for our cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms," said Matt Stanton, Ph.D., chief scientific officer. "We've made rapid progress across our platforms and look forward to presenting further updates at the meeting."

Oral Presentation

Title: Highly Specific, In Vivo Delivery to T-Cells with Cell-Targeted Lipid Nanoparticles
Session: Targeting Specific Cell Types with Nonviral Delivery
Session Location: Room 314-317
Session Date/Time: Saturday, May 11, 8:00 a.m. – 9:45 a.m. ET
Presentation Time: 8:35 a.m. – 9:10 a.m. ET

Poster Presentations

Title: iqDNA Is an Engineered DNA Cargo That Avoids Innate Immune Activation While Retaining Durable Transgene Expression
Session: Challenges to Immunological Responses to Therapeutic Interventions
Session Date/Time: Thursday, May 9, 2024, 12:00 p.m. ET – 7:00 p.m. ET
Abstract Number : 1294

Title: Rapid Enzymatic Synthesis and Scaling of DNA Gene Therapy Molecules
Session: Nonviral Therapeutic Gene Delivery and Synthetic/Molecular Conjugates
Session Date/Time: Thursday, May 9, 12:00 p.m. – 7:00 p.m. ET
Abstract Number : 1232

Title: Optimization of Ionizable Lipid Structure to Modulate ApoE Binding and Enable Stealth Lipid Nanoparticles
Session: Other Nonviral Delivery
Session Date/Time: Thursday, May 9, 12:00 p.m. ET – 7:00 p.m. ET
Abstract Number : 1240

Title: Development of Cell-Targeted Lipid Nanoparticles Using Antibody Derived Ligands for Targeted Delivery to Hepatocytes and Immune Cells
Session: Nonviral Therapeutic Gene Delivery and Synthetic/Molecular Conjugates
Session: Other Nonviral Delivery
Session Date/Time: Thursday, May 9, 12:00 p.m. ET – 7:00 p.m. ET
Abstract Number : 1241

Title: In Vivo High-Throughput Pooled Screening of Transcriptional Regulatory Elements for Gene Therapy
Session: Nonviral Therapeutic Gene Delivery and Synthetic/Molecular Conjugates
Session Date/Time: Thursday, May 9, 12:00 p.m. ET – 7:00 p.m. ET
Abstract Number : 1233

The ASGCT abstracts are available to the public here . A copy of the presentation materials will be added to the "Our Scientific Presentations" section of the company's website here on the day of each presentation.

About Generation Bio

Generation Bio is innovating non-viral genetic medicines to provide durable and redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). With these platforms, Generation Bio aims to develop the next wave of non-viral genetic medicines to support its mission to extend the reach of genetic medicine to more people living with more diseases, around the world.

For more information, please visit www.generationbio.com .

Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

GBIO
The Conversation (0)

Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results

- Oral presentation at ASGCT described selective, high levels of therapeutic transgene   delivery to T cells in vivo by cell-targeted lipid nanoparticle (ctLNP)

- ASGCT poster presentations described immune-quiet DNA (iqDNA) as partially single-stranded, produced by flexible, scalable, proprietary rapid enzymatic synthesis

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting

  • Data presented show immune-quiet DNA (iqDNA) is a partially single-stranded DNA cargo that maintains expression while evading innate immune sensors
  • Rapid enzymatic synthesis continues to improve iqDNA performance through process development and the identification of novel structural elements
  • Data on cell-targeted LNP (ctLNP) in vivo delivery of therapeutic transgenes to T cells to be discussed in an oral presentation on Saturday, May 11

Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented five posters on its immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms as well as its enzymatic synthesis manufacturing at the American Society of Gene and Cell Therapy (ASGCT) 27 th Annual Meeting. A sixth presentation on the company's ctLNP platform will be discussed in an oral presentation on Saturday, May 11.

"The data we're presenting at ASGCT showcase some important mechanistic underpinnings of our novel platforms, which we believe have the potential to overcome the core challenges facing the field of genetic medicine," said Matt Stanton, Ph.D., chief scientific officer of Generation Bio. "We believe immune-quiet DNA cargo and highly selective, targeted LNP delivery are the tools required to unlock the full potential of non-viral genetic medicines, and we are applying them to our current portfolio of programs in T cells, hematopoietic stem cells, and hepatocytes."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on March 31, 2025.

Two individuals were hired by Adicet in March 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 38,600 shares of Adicet's common stock with an exercise price of $0.76 per share, the closing price of Adicet's common stock as reported by Nasdaq on March 31, 2025. One-fourth of the shares underlying each employee's option will vest on the one-year anniversary of each recipient's start date and thereafter the remaining three-fourths of the shares underlying each employee's option will vest in thirty-six substantially equal monthly installments, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the recipient's start date, in each case, subject to each such employee's continued employment with Adicet on such vesting dates.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
AbbVie to Host First-Quarter 2025 Earnings Conference Call

AbbVie to Host First-Quarter 2025 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025 before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An archived edition of the session will be available later that day.

About AbbVie

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025.

Details of the event are as follows:
Panel: "CAR T Approaches in the Autoimmune Space"
Date: Monday, April 7, 2025
Time: 3:00 p.m. ET

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Issues Open Letter to Atea's Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers

Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025

Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025

  • Four expert-led educational events with Allergan Medical Institute (AMI), Science of Aging TM and Allergan Aesthetics (AA) Global Medical Affairs
  • AMI symposia will focus on a new Allergan Aesthetics (AA) Signature Program and celebrate 10 years of MD Codes™, with live injection sessions and fireside chat with world-renowned plastic surgeon Dr. Maurício de Maio
  • Eleven E-Poster data presentations and Meet the Expert sessions with Global experts live from the Allergan Aesthetics booth

Allergan Aesthetics, an AbbVie company, the industry leader in aesthetics globally, demonstrates how to elevate the patient experience and achieve optimal treatment outcomes with new AA Signature program at the Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from Thursday, March 27Saturday, March 29, 2025 .

Activities will center around the new AA Signature program - an innovative approach to treatment planning harnessing the power of Allergan Aesthetics advanced portfolio to address different patient needs, including Lift, Definition and Skin Quality , and a celebration of 10 years of MD Codes™, which has revolutionized aesthetic medicine with innovative methodology to guide injectors' technique and elevate patient outcomes.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Bcal Diagnostics Limited

BCAL Diagnostics Launches BREASTEST plus - Generating First Revenues

BCAL Diagnostics Limited (ASX: BDX) (“BCAL” or “the Company”), an Australian and US-based biotechnology company pioneering non-invasive breast cancer diagnostics, is pleased to announce the commercial launch of BREASTEST plus. This first-in-class blood test is available from Thursday, 27 March 2025 and will be used alongside standard-of-care imaging in breast cancer screening and diagnostics. The Company is pleased that this launch has been achieved within the previously announced target timeframe of having the test commercially available in Australia by the end of 1Q CY2025.

Keep reading...Show less

Latest Press Releases

Related News

×